Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Treace Medical Concepts to announce earnings of ($0.26) per share and revenue of $47.80 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.
Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.06. The firm had revenue of $45.38 million for the quarter, compared to analyst estimates of $44.02 million. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. On average, analysts expect Treace Medical Concepts to post ($0.83) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.
Treace Medical Concepts Stock Performance
TMCI stock opened at $4.50 on Thursday. The company has a quick ratio of 1.95, a current ratio of 2.90 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $292.68 million, a price-to-earnings ratio of -4.84 and a beta of 1.59. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $6.55. The firm has a 50 day moving average of $4.42 and a two-hundred day moving average of $3.27.
Insiders Place Their Bets
In related news, CEO John Treace bought 11,000 shares of Treace Medical Concepts stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average cost of $4.34 per share, for a total transaction of $47,740.00. Following the acquisition, the chief executive officer owned 7,404,383 shares in the company, valued at $32,135,022.22. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders purchased 55,944 shares of company stock valued at $246,841. 23.42% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on TMCI shares. Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Truist Financial upped their price objective on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a report on Monday, August 10th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Treace Medical Concepts presently has a consensus rating of “Reduce” and a consensus target price of $5.17.
Get Our Latest Stock Report on TMCI
About Treace Medical Concepts
Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company’s technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.
Treace’s primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.
Featured Stories
- Five stocks we like better than Treace Medical Concepts
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
